COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,796 Articles (22,527 medRxiv, 8,269 bioRxiv)

Most recent first Previous |  Page 1492: Articles 14911-14920  | Next

Prevalence and source analysis of COVID-19 misinformation of 138 countries
Al-Zaman, M. S.
10.1101/2021.05.08.21256879 — Posted: 2021-05-12
Fixed dosing of tocilizumab in ICU admitted COVID-19 patients is a superior choice compared to bodyweight based dosing; an observational population pharmacokinetic and pharmacodynamic study
Moes, D. J. A. R., van Westerloo, D. J., Arend, S. M., Swen, J. J., de Vries, A., Guchelaar, H.-J., Joosten, S. A., de Boer, M. G. J., van Gelder, T., van Paassen, J.
10.1101/2021.05.10.21256933 — Posted: 2021-05-12
A model to analyze rideshare data to surveil novel strains of SARS-CoV-2
Safranek, C. W., Scheinker, D.
10.1101/2021.05.07.21256856 — Posted: 2021-05-12
SIR-based model with multiple imperfect vaccines.
Aguilar-Canto, F. J., Avila Ponce de Leon, U., Avila-Vales, E.
10.1101/2021.05.07.21256860 — Posted: 2021-05-12
Neutralizing response against E484K variant after original SARS-CoV-2 infection
Hayashi, T., Yaegashi, N., Konishi, I.
10.1101/2021.05.07.21256803 — Posted: 2021-05-12
Meta-analysis of rapid direct-to-PCR assays for the qualitative detection of SARS-CoV-2
Trevor, R. A., Grippon, S., Chen, H., Koh, L., Borley, D., Oladimeji, P., Kidd, S., Martin, J.
10.1101/2021.05.07.21256745 — Posted: 2021-05-12
SARS-CoV-2 antibodies rapid tests: a valuable epidemiological tool in challenging settings
Saluzzo, F., Mantegani, P., Poletti De Chaurand, V., Quaresima, V., Cugnata, F., Di Serio, C., Mace, A., de Vos, M., Sacks, J. A., Cirillo, D. M.
10.1101/2021.05.08.21256893 — Posted: 2021-05-12
No excess mortality detected in rural Bangladesh in 2020 from repeated surveys of a population of 81,000
Barnwal, P., Yao, Y., Wang, Y., Juy, N. A., Raihan, S., Haque, M. A., van Geen, A.
10.1101/2021.05.07.21256865 — Posted: 2021-05-12
MASK MANDATES REDUCE COVID-19 MORTALITY: Analysis of 37 States and the District of Columbia, with a further analysis of the impact of demographic and medical factors on efficacy.
Maloney, M. J.
10.1101/2021.05.09.21256922 — Posted: 2021-05-12
INFLUENCE OF NOVEL CORONAVIRUS DISEASE (COVID-19) ON PARKINSONS DISEASE: SYSTEMATIC REVIEW
Jaiswal, V., Alquraish, D., Nagpal, S., MUKHERJEE, D., Shrestha, P. S., Velazco, D. S., Guntipalli, P., Bhatnagar, A., Savani, S., Halilaj, E. H., Ruxmohan, S.
10.1101/2021.05.09.21256929 — Posted: 2021-05-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).